| Founded | 2010, Qingdao, China |
|---|---|
| Global Reach | 100+ countries |
| Certifications | GMP, FDA VMF, CEP, ISO |
| Core Products | UDCA, veterinary APIs, antibiotics, nutrition ingredients |
| LATAM-Specific | ANVISA/COFEPRIS support, ES/PT docs |
Latin America's pharmaceutical market is a significant and growing opportunity, with the Big Four markets (Brazil, Mexico, Argentina, and Colombia) projected to approach USD 100 billion by 2027. Brazil alone is the world's eighth-largest pharmaceutical market, valued at approximately BRL 249 billion (USD 45 billion) in 2024 with a projected 9.7% CAGR through 2029. Mexico, Latin America's largest pharmaceutical exporter, has over 900 pharmaceutical companies and represents the region's second-largest market. India's pharmaceutical exports to Brazil reached USD 916 million in 2024, growing at 17-18% annually, demonstrating the sustained trade flow of APIs into Latin America.
KingWish has been supplying Latin American pharmaceutical manufacturers for over a decade, navigating the region's diverse regulatory landscape that ranges from ANVISA's rigorous GMP inspection requirements in Brazil to COFEPRIS's third-party certification acceptance in Mexico. We have invested in the specific capabilities that Latin American buyers need: Spanish and Portuguese documentation, understanding of Mercosur trade facilitation mechanisms, logistics routing optimized for Panama Canal transit and regional distribution hubs, and regulatory support for the full spectrum of Latin American drug registration processes.
Brazil's ANVISA, widely regarded as one of the world's most demanding regulatory agencies, requires on-site GMP inspections for API manufacturers — a process that can take 18-30 months from initial request. In March 2024, ANVISA introduced a regulatory reliance framework accepting prior marketing authorizations from FDA, EMA, and Health Canada to streamline clinical/non-clinical review, though the GMP certification requirement remains. Mexico's COFEPRIS, by contrast, accepts third-party GMP certifications from FDA and EMA, simplifying the registration pathway. KingWish's existing FDA VMF and CEP certifications provide a strong foundation for Latin American registrations, as our manufacturing standards have already been audited against internationally recognized benchmarks.
Latin American pharmaceutical manufacturers cover a broad therapeutic range. KingWish's product portfolio aligns with the region's highest-volume API import categories.
UDCA for hepatobiliary formulations. With rising NAFLD and metabolic disease rates across Latin America, UDCA formulations are in growing demand. KingWish is China's largest UDCA supplier, offering USP/EP-grade material with full DMF documentation and stability data for Zone IVb climate conditions.
Spectinomycin HCl, amoxicillin trihydrate, tilmicosin phosphate, and gentamycin sulphate. Brazil is one of the world's largest beef and poultry producers, and Latin America's livestock sector generates consistent demand for veterinary antibiotic APIs across the region.
Amoxicillin trihydrate, ampicillin trihydrate, azithromycin, amikacin sulphate, and ceftiofur HCl. Brazil's public health system (SUS) is one of the world's largest single purchasers of generic medicines, driving sustained demand for antibiotic APIs.
Amino acids, vitamins, and mineral premixes. Latin America's nutraceutical market is expanding rapidly, with Brazil and Mexico leading growth. Our feed-grade products support the region's animal protein production sector.
Market context: Latin America's pharmaceutical import dependency creates sustained demand for qualified API suppliers. The Mercosur trade bloc (Brazil, Argentina, Uruguay, Paraguay) facilitates reduced-tariff trade within South America, and Panama's Colón Free Zone serves as a distribution hub for Central American and Caribbean markets. Chile's Valparaiso port and logistics infrastructure make it an alternative entry point for Pacific coast distribution. KingWish's logistics experience across these routes ensures reliable delivery regardless of destination country.
Latin America's regulatory landscape varies significantly by country. KingWish provides documentation packages tailored to the requirements of each national regulatory authority.
We prepare ANVISA-specific documentation packages including the comprehensive DMF in CTD format, stability data per ICH Zone IVb (hot/humid) conditions, and Certificates of Pharmaceutical Product. Our facilities are prepared for ANVISA GMP inspections. We leverage ANVISA's RDC 2024 reliance framework where our existing FDA/EMA/CEP certifications apply.
Mexico accepts third-party GMP certifications (FDA, EMA), which streamlines the registration pathway for KingWish products. We provide COFEPRIS-compliant documentation packages including GMP certificates, DMFs, and Certificates of Analysis. Our regulatory team is familiar with COFEPRIS's registration submission requirements.
We provide translated technical documentation in Spanish and Portuguese including Certificates of Analysis, GMP certificates, Certificates of Origin, quality agreements, and technical dossiers. All translations use accredited services familiar with Latin American pharmaceutical regulatory terminology.
We support registrations with INVIMA (Colombia), ANMAT (Argentina), ISP (Chile), DIGEMID (Peru), and ARCSA (Ecuador). Documentation packages are customized to each authority's requirements, including local pharmacopoeia references where applicable.
Payment terms: T/T (wire transfer) or irrevocable Letter of Credit. We work with major international banks and can accommodate Latin American banking requirements. Minimum order quantities vary by product. Sample quantities (50-100g) available for initial evaluation and method development. For Brazilian importers, we ensure all documentation complies with ANVISA import licensing requirements under RDC 81/2008.